drugset / Trial / NCT00239005
Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
This open, multi-center randomized controlled study is designed to investigate the quality of life in patients with mycophenolate mofetil (MMF)-induced gastrointestinal (GI) adverse events after converting to enteric-coated mycophenolate sodium (EC-MPS).
Timeline
- Start
- 2005-09
- Primary completion
- 2008-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mycophenolate Mofetil | Small molecule | 250 mg | — |
| Comparator | Mycophenolate Mofetil | Small molecule | 500 mg | — |
| Subject | Mycophenolate Sodium | Unknown | 180 mg | Oral |
| Subject | Mycophenolate Sodium | Unknown | 360 mg | Oral |
Indications
No indication recorded.